Clinical Trial

Ethical Issues of Using Gene Therapy in the Treatment of AMD

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 24, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD). This involves questioning its beneficence/non-maleficence ratio given the limited experience with this innovative technology and its irreversible effects, requiring a surgical procedure for administration. Additionally, the study explores patient autonomy in decision-making concerning complex therapeutic approaches and how patients should be supported to best uphold this autonomy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-26.
Status change: Not Yet Recruiting → Recruiting 2026-06-23
Trial Details
NCT Number NCT07004361
Lead Sponsor Nantes University Hospital
Conditions Exudative Age-related Macular Degeneration
Enrollment 30 participants
Start Date 2025-07-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-24